PT-141 (Bremelanotide) by quarter
Coverage and results for PT-141 (Bremelanotide) quarter by quarter. Read the supplier-count column beside the median: a quarter where the compound mix changed is not comparable with the one before it, and the index cannot hold that constant retrospectively.
| Quarter | Batches | Reports | Median purity % | IQR pp | Suppliers | Flagged | What changed in the index |
|---|---|---|---|---|---|---|---|
| 2024-Q1 | 2 | 16 | 99.60 | 0.50 | 2 | 5 | Backfill quarter. Reports assayed earlier were accepted retrospectively where custody could be documented. |
| 2024-Q2 | 1 | 7 | 99.10 | 0.36 | 1 | 0 | First quarter of live submission. |
| 2024-Q3 | 4 | 31 | 98.77 | 1.51 | 3 | 9 | Nordanalyt Laboratories began contributing. |
| 2024-Q4 | 1 | 10 | 99.67 | 0.49 | 1 | 10 | Impurity-fingerprint matching introduced; first shared-bulk links published. |
| 2025-Q1 | 4 | 16 | 98.44 | 1.28 | 3 | 10 | Anomaly rule set expanded from seven rules to eleven. |
| 2025-Q2 | 2 | 15 | 99.20 | 0.59 | 2 | 4 | Gravimetric mass-balance reconciliation became mandatory on new records. |
| 2025-Q3 | 5 | 19 | 98.38 | 0.94 | 5 | 14 | Kestrel Bioanalytical began contributing; gradient-length normalisation introduced. |
| 2025-Q4 | 4 | 18 | 99.90 | 0.69 | 3 | 11 | Provenance classification became a required field. |
| 2026-Q1 | 2 | 13 | 99.93 | 0.23 | 2 | 3 | Rule AX-R12 added. Dataset v2 schema published. |
| 2026-Q2 | 6 | 45 | 99.19 | 0.65 | 4 | 16 | Buyer-sourced sensitivity analysis added to every supplier scorecard. |
| 2026-Q3 | 1 | 10 | 99.78 | 0.52 | 1 | 0 | Quarter in progress. Aggregates for this quarter are provisional. |
Median purity by quarter
Quarters with fewer than two purity records are gaps in the line rather than zeroes. A trend across 11 points, most of them thin, is a shape and not a finding.